DK1543038T4 - Proteinoprensning - Google Patents

Proteinoprensning Download PDF

Info

Publication number: DK1543038T4
Authority: DK; Denmark
Prior art keywords: protein purification; purification; protein
Prior art date: 2002-09-11

Application number

DK03795664.6T

Other languages

English (en)

Other versions

DK1543038T3 (da

Inventor

Paul J Mcdonald

Rhona O'leary

Jefferson C Emery

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-11

Filing date

2003-09-08

Publication date

2020-11-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31994112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1543038(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-09-08 Application filed by Genentech Inc filed Critical Genentech Inc

2017-07-10 Application granted granted Critical

2017-07-10 Publication of DK1543038T3 publication Critical patent/DK1543038T3/da

2020-11-09 Publication of DK1543038T4 publication Critical patent/DK1543038T4/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK03795664.6T 2002-09-11 2003-09-08 Proteinoprensning DK1543038T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41033402P	2002-09-11	2002-09-11
PCT/US2003/028064 WO2004024866A2 (en)	2002-09-11	2003-09-08	Protein purification

Publications (2)

Publication Number	Publication Date
DK1543038T3 DK1543038T3 (da)	2017-07-10
DK1543038T4 true DK1543038T4 (da)	2020-11-09

Family

ID=31994112

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK03795664.6T DK1543038T4 (da)	2002-09-11	2003-09-08	Proteinoprensning
DK10187798.3T DK2332996T3 (da)	2002-09-11	2003-09-08	Oprensning af anti-Her2-antistoffer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK10187798.3T DK2332996T3 (da)	2002-09-11	2003-09-08	Oprensning af anti-Her2-antistoffer

Country Status (14)

Country	Link
US (10)	US8044017B2 (da)
EP (3)	EP3388452A3 (da)
JP (7)	JP5303092B2 (da)
AU (2)	AU2003265994B2 (da)
CA (1)	CA2496060C (da)
CY (1)	CY1119024T1 (da)
DK (2)	DK1543038T4 (da)
ES (2)	ES2527616T3 (da)
HU (1)	HUE033623T2 (da)
IL (5)	IL262513B (da)
LT (1)	LT1543038T (da)
PT (1)	PT1543038T (da)
SI (1)	SI1543038T2 (da)
WO (1)	WO2004024866A2 (da)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7672730B2 (en) *	2001-03-08	2010-03-02	Advanced Neuromodulation Systems, Inc.	Methods and apparatus for effectuating a lasting change in a neural-function of a patient
ES2527616T3 (es) *	2002-09-11	2015-01-27	Genentech, Inc.	Purificación de anticuerpos anti-HER2
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
BRPI0518104B8 (pt)	2005-01-21	2021-05-25	Genentech Inc	artigo industrializado e uso de anticorpo her2
RU2404806C2 (ru) *	2005-02-23	2010-11-27	Дженентек, Инк.	Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
TW200642695A (en) *	2005-03-08	2006-12-16	Genentech Inc	Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
AR054428A1 (es) *	2005-03-08	2007-06-27	Pharmacia & Upjohn Co Llc	Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina
EP1871726A2 (en) *	2005-03-23	2008-01-02	Bio-Rad Laboratories, Inc.	Diverse chemical libraries bound to small particles with paramagnetic properties
US20090247421A1 (en) *	2005-03-23	2009-10-01	Egisto Boschetti	Diverse chemical libraries bound to small particles with paramagnetic properties
CN101218247A (zh) *	2005-04-11	2008-07-09	米德列斯公司	利用hcic和离子交换层析的蛋白质纯化
JP2006316040A (ja)	2005-05-13	2006-11-24	Genentech Inc	Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
TWI391399B (zh)	2005-05-25	2013-04-01	Hoffmann La Roche	測定溶離多肽之鹽濃度之方法
PE20070207A1 (es) *	2005-07-22	2007-03-09	Genentech Inc	Tratamiento combinado de los tumores que expresan el her
JP2010501623A (ja)	2006-08-28	2010-01-21	アレストレーディングソシエテアノニム	Ｆｃ含有タンパク質の精製法
CA2677108A1 (en)	2007-03-02	2008-09-12	Genentech, Inc.	Predicting response to a her inhibitor
RU2009148891A (ru)	2007-06-01	2011-07-20	Ф.Хоффманн-Ля Рош Аг (Ch)	Очистка иммуноглобулина
WO2008154249A2 (en)	2007-06-08	2008-12-18	Genentech, Inc.	Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) *	2007-06-08	2017-01-24	Genentech, Inc.	Gene expression markers of tumor resistance to HER2 inhibitor treatment
CL2008002053A1 (es)	2007-07-17	2009-05-22	Hoffmann La Roche	Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) *	2007-07-17	2009-05-29	Hoffmann La Roche	Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
MX2010004740A (es) *	2007-10-30	2010-05-27	Genentech Inc	Purificacion de anticuerpos por cromatografia de intercambio cationico.
CN101225102B (zh) *	2008-01-21	2013-07-31	南昌大学	罗非鱼鱼皮多肽螯合锌盐的制备方法
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
JP5646457B2 (ja)	2008-04-29	2014-12-24	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリン及びその使用
JP2011523853A (ja)	2008-06-03	2011-08-25	アボット・ラボラトリーズ	二重可変ドメイン免疫グロブリン及びその使用
RU2010153578A (ru)	2008-06-03	2012-07-20	Эбботт Лэборетриз (Us)	Иммуноглобулины с двойными вариабельными доменами и их применение
BRPI0812682A2 (pt)	2008-06-16	2010-06-22	Genentech Inc	tratamento de cáncer de mama metastático
BRPI0923541A2 (pt)	2008-12-22	2016-01-26	Hoffmann La Roche	purificação de imunoglobulina
EP2408817B1 (en)	2009-03-20	2016-03-16	F.Hoffmann-La Roche Ag	Bispecific anti-her antibodies
US20120121586A1 (en)	2009-05-29	2012-05-17	Astrid Kiermaier	Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2456789A1 (en) *	2009-07-24	2012-05-30	F. Hoffmann-La Roche AG	Optimizing the production of antibodies
IN2012DN02737A (da)	2009-09-01	2015-09-11	Abbott Lab
PE20121531A1 (es)	2009-10-15	2012-12-22	Abbott Lab	Inmunoglobulinas con dominio variable dual
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
TWI400128B (zh) *	2009-11-30	2013-07-01	Univ Tamkang	蛋白質純化方法
SG183333A1 (en)	2010-02-18	2012-09-27	Genentech Inc	Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
GB201012603D0 (en)	2010-07-27	2010-09-08	Ucb Pharma Sa	Protein purification
WO2012015912A1 (en) *	2010-07-30	2012-02-02	Medimmune, Llc	Method for purifying active polypeptides or immunocojugates
BR112013002578A2 (pt)	2010-08-03	2019-05-14	Abbvie Inc.	imunoglobinas de domínio variável duplo e usos das mesmas
MX2013002270A (es)	2010-08-26	2013-05-14	Abbvie Inc	Inmonoglubinas de dominio variable doble y usos de las mismas.
RU2566267C2 (ru)	2010-09-14	2015-10-20	Ф. Хоффманн-Ля Рош Аг	Способ очистки пегилированного эритропоэтина
EP2643353A1 (en)	2010-11-24	2013-10-02	Novartis AG	Multispecific molecules
WO2012082933A1 (en) *	2010-12-15	2012-06-21	Baxter International, Inc.	Eluate collection using conductivity gradient
BR112013012422A2 (pt) *	2010-12-21	2016-08-30	Hoffmann La Roche	"método para produzir uma preparação de anticorpo e anticorpo anti-her2"
JP5766296B2 (ja)	2010-12-23	2015-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
US20140107321A1 (en) *	2011-05-26	2014-04-17	Dr. Reddy's Laboratories Limited	Purification of antibodies
CA2842375A1 (en)	2011-08-17	2013-02-21	Erica Jackson	Neuregulin antibodies and uses thereof
JP6116565B2 (ja)	2011-08-25	2017-04-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	陽イオンおよび陰イオン交換クロマトグラフィー法
PT4241849T (pt)	2011-10-14	2024-10-30	Hoffmann La Roche	Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
WO2013063229A1 (en)	2011-10-25	2013-05-02	The Regents Of The University Of Michigan	Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
CA2857114A1 (en)	2011-11-30	2013-06-06	Genentech, Inc.	Erbb3 mutations in cancer
EP2788500A1 (en)	2011-12-09	2014-10-15	F.Hoffmann-La Roche Ag	Identification of non-responders to her2 inhibitors
CN104159920A (zh)	2011-12-30	2014-11-19	艾伯维公司	针对il-13和/或il-17的双重可变结构域免疫球蛋白
CN104220457A (zh)	2012-03-27	2014-12-17	霍夫曼-拉罗奇有限公司	涉及her3抑制剂的诊断和治疗
TW202210507A (zh)	2012-11-01	2022-03-16	美商艾伯維有限公司	抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
EP3511718A1 (en)	2012-11-30	2019-07-17	F. Hoffmann-La Roche AG	Pd-l1 inhibitor
WO2014118685A2 (en) *	2013-01-29	2014-08-07	Dr. Reddy's Laboratories Limited	Method of altering the acidic variant content of antibody
HK1219964A1 (zh)	2013-03-08	2017-04-21	Genzyme Corporation	治疗性蛋白药物物质的整合连续制造
EP2970459A2 (en)	2013-03-15	2016-01-20	AbbVie Inc.	Dual specific binding proteins directed against il-1beta and il-17
AU2013203043B2 (en) *	2013-03-15	2016-10-06	Takeda Pharmaceutical Company Limited	Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AR095863A1 (es)	2013-04-16	2015-11-18	Genentech Inc	Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
JP6462681B2 (ja)	2013-07-12	2019-01-30	ジェネンテック，インコーポレイテッド	イオン交換クロマトグラフィーのインプットの最適化の解明
CN104628846B (zh) *	2013-11-06	2019-12-06	三生国健药业（上海）股份有限公司	重组蛋白质的纯化方法
TWI709569B (zh)	2014-01-17	2020-11-11	美商健臻公司	無菌層析樹脂及其用於製造方法的用途
TWI709570B (zh)	2014-01-17	2020-11-11	美商健臻公司	無菌層析法及製法
CA2946860A1 (en)	2014-04-25	2015-10-29	Genentech, Inc.	Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
WO2015195452A2 (en)	2014-06-16	2015-12-23	Emd Millipore Corporation	Single-pass filtration systems and processes
WO2015195453A2 (en)	2014-06-16	2015-12-23	Emd Millipore Corporation	Methods for increasing the capacity of flow-through processes
CN115463546A (zh)	2014-06-25	2022-12-13	Emd 密理博公司	过滤器元件、切向流过滤系统、产生进料筛网的方法
KR102079585B1 (ko)	2014-08-29	2020-02-21	이엠디 밀리포어 코포레이션	잔류물의 재순환을 이용한 싱글 패스 접선 유동 여과 시스템 및 접선 유동 여과 시스템
EP3010626B1 (en)	2014-08-29	2022-12-14	EMD Millipore Corporation	Processes for filtering liquids using single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
WO2016094881A2 (en)	2014-12-11	2016-06-16	Abbvie Inc.	Lrp-8 binding proteins
JP6699085B2 (ja) *	2015-03-25	2020-05-27	東ソー株式会社	Ｆｃ結合性タンパク質の精製方法
WO2016172855A1 (zh) *	2015-04-28	2016-11-03	深圳翰宇药业股份有限公司	多肽混合物高效液相色谱分析方法
FI3302551T3 (fi)	2015-05-30	2024-08-27	Hoffmann La Roche	Menetelmiä her2-positiivisen, aiemmin hoitamattoman metastaattisen rintasyövän hoitamiseksi
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017087280A1 (en)	2015-11-16	2017-05-26	Genentech, Inc.	Methods of treating her2-positive cancer
US20190151346A1 (en)	2016-05-10	2019-05-23	INSERM (Institute National de la Santé et de la Recherche Médicale)	Combinations therapies for the treatment of cancer
ES2925059T3 (es)	2016-06-09	2022-10-13	Emd Millipore Corp	Elementos de filtro de trayectoria radial, sistemas y métodos de uso de los mismos
PL3484911T3 (pl)	2016-07-15	2021-03-08	F. Hoffmann-La Roche Ag	Sposób oczyszczania PEGylowanej erytropoetyny
SI3570884T1 (sl)	2017-01-17	2021-02-26	Genentech, Inc.	Subkutane formulacije protiteles HER2
CN114984206A (zh)	2017-03-02	2022-09-02	基因泰克公司	Her2阳性乳腺癌的辅助治疗
EP3843869A1 (en)	2018-08-31	2021-07-07	Genzyme Corporation	Sterile chromatography resin and use thereof in manufacturing processes
KR20250151568A (ko)	2020-06-29	2025-10-21	제넨테크, 인크.	퍼투주맙 + 트라스투주맙 고정 용량 조합

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
USRE30985E (en)	1978-01-01	1982-06-29		Serum-free cell culture media
FR2413974A1 (fr)	1978-01-06	1979-08-03	David Bernard	Sechoir pour feuilles imprimees par serigraphie
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4675187A (en)	1983-05-16	1987-06-23	Bristol-Myers Company	BBM-1675, a new antibiotic complex
DD266710A3 (de)	1983-06-06	1989-04-12	Ve Forschungszentrum Biotechnologie	Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4879231A (en)	1984-10-30	1989-11-07	Phillips Petroleum Company	Transformation of yeasts of the genus pichia
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5091178A (en)	1986-02-21	1992-02-25	Oncogen	Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
GB8610600D0 (en)	1986-04-30	1986-06-04	Novo Industri As	Transformation of trichoderma
JP3040121B2 (ja)	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
WO1990003430A1 (en)	1988-09-23	1990-04-05	Cetus Corporation	Cell culture medium for enhanced cell growth, culture longevity and product expression
US5028696A (en)	1988-10-28	1991-07-02	Torres Anthony R	Ion exchange and separation method
EP0402226A1 (en)	1989-06-06	1990-12-12	Institut National De La Recherche Agronomique	Transformation vectors for yeast yarrowia
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en)	1989-06-29	1996-10-30	Medarex, Inc.	Bispecific reagents for aids therapy
WO1991002049A1 (en) *	1989-08-04	1991-02-21	Peter Grandics	An integrated cell culture-protein purification system for the automated production and purification of cell culture products
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2102511A1 (en)	1991-05-14	1992-11-15	Paul J. Higgins	Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
ATE297465T1 (de)	1991-11-25	2005-06-15	Enzon Inc	Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ATE295420T1 (de)	1992-02-06	2005-05-15	Chiron Corp	Marker für krebs und biosynthetisches bindeprotein dafür
US5279823A (en)	1992-06-08	1994-01-18	Genentech, Inc.	Purified forms of DNASE
ATE149570T1 (de)	1992-08-17	1997-03-15	Genentech Inc	Bispezifische immunoadhesine
JPH07505787A (ja) *	1993-02-05	1995-06-29	ダラテク・プロプライエタリー・リミテッド	ファスキオラ種から取得可能なポリペプチド類，およびワクチン，処置法およびそのｄｎａ配列
US5534615A (en)	1994-04-25	1996-07-09	Genentech, Inc.	Cardiac hypertrophy factor and uses therefor
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6150507A (en) *	1995-03-23	2000-11-21	Biopure Corporation	Method for producing a purified hemoglobin product
ES2434840T3 (es)	1995-07-27	2013-12-17	Genentech, Inc.	Formulación de proteína liofilizada isotónica estable
PT1864999E (pt)	1996-11-27	2009-06-25	Genentech Inc	Purificação por afinidade de um polipéptido numa matriz de proteína a
JP2001507937A (ja) *	1997-01-14	2001-06-19	ヒューマンジノームサイエンシーズ，インコーポレイテッド	腫瘍壊死因子レセプター６αおよび腫瘍壊死因子レセプター６β
CN1305896C (zh) *	1998-05-06	2007-03-21	基因技术股份有限公司	用离子交换层析纯化蛋白质
US6433144B1 (en)	1999-01-12	2002-08-13	Viragen, Inc.	Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
US6451987B1 (en) *	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
US6451978B2 (en) *	2000-01-21	2002-09-17	Biovitrum Ab	Purification of antithrombin-III-α and β
US6417355B1 (en)	2001-04-11	2002-07-09	The United States Of America As Represented By The Secretary Of The Navy	Geminal-dinitro-1-5 diazocine derivatives
ES2527616T3 (es) *	2002-09-11	2015-01-27	Genentech, Inc.	Purificación de anticuerpos anti-HER2
AR092630A1 (es) *	2012-09-19	2015-04-29	Genentech Inc	Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas

2003
- 2003-09-08 ES ES10187798.3T patent/ES2527616T3/es not_active Expired - Lifetime
- 2003-09-08 SI SI200332527T patent/SI1543038T2/sl unknown
- 2003-09-08 DK DK03795664.6T patent/DK1543038T4/da active
- 2003-09-08 JP JP2004536141A patent/JP5303092B2/ja not_active Expired - Lifetime
- 2003-09-08 EP EP17172929.6A patent/EP3388452A3/en not_active Withdrawn
- 2003-09-08 HU HUE03795664A patent/HUE033623T2/en unknown
- 2003-09-08 EP EP10187798.3A patent/EP2332996B1/en not_active Expired - Lifetime
- 2003-09-08 WO PCT/US2003/028064 patent/WO2004024866A2/en not_active Ceased
- 2003-09-08 CA CA2496060A patent/CA2496060C/en not_active Expired - Lifetime
- 2003-09-08 PT PT37956646T patent/PT1543038T/pt unknown
- 2003-09-08 IL IL262513A patent/IL262513B/en unknown
- 2003-09-08 AU AU2003265994A patent/AU2003265994B2/en not_active Expired
- 2003-09-08 EP EP03795664.6A patent/EP1543038B2/en not_active Expired - Lifetime
- 2003-09-08 DK DK10187798.3T patent/DK2332996T3/da active
- 2003-09-08 LT LTEP03795664.6T patent/LT1543038T/lt unknown
- 2003-09-08 ES ES03795664T patent/ES2629602T5/es not_active Expired - Lifetime
- 2003-09-10 US US10/659,825 patent/US8044017B2/en active Active
2005
- 2005-02-22 IL IL167041A patent/IL167041A/en active IP Right Grant
2009
- 2009-12-09 JP JP2009279954A patent/JP2010053154A/ja not_active Withdrawn
2010
- 2010-07-01 AU AU2010202784A patent/AU2010202784A1/en not_active Abandoned
2011
- 2011-10-04 US US13/252,952 patent/US8710196B2/en not_active Expired - Lifetime
2012
- 2012-08-17 JP JP2012181141A patent/JP2012214523A/ja not_active Withdrawn
2014
- 2014-03-18 US US14/218,445 patent/US9868760B2/en not_active Expired - Lifetime
2015
- 2015-04-03 JP JP2015076578A patent/JP2015131847A/ja not_active Withdrawn
- 2015-04-30 IL IL238541A patent/IL238541A0/en unknown
- 2015-04-30 IL IL238540A patent/IL238540A0/en unknown
2017
- 2017-01-16 JP JP2017005044A patent/JP2017095497A/ja not_active Withdrawn
- 2017-06-21 CY CY20171100652T patent/CY1119024T1/el unknown
- 2017-12-08 US US15/836,695 patent/US10501491B2/en not_active Expired - Lifetime
2018
- 2018-01-28 IL IL257192A patent/IL257192B/en active IP Right Grant
- 2018-10-10 JP JP2018191584A patent/JP2019043953A/ja not_active Withdrawn
2019
- 2019-08-06 US US16/533,593 patent/US20190352331A1/en not_active Abandoned
- 2019-08-06 US US16/533,621 patent/US20190352333A1/en not_active Abandoned
- 2019-08-06 US US16/533,610 patent/US20190352332A1/en not_active Abandoned
2021
- 2021-01-08 US US17/145,235 patent/US20210171571A1/en not_active Abandoned
- 2021-01-08 US US17/145,231 patent/US20210130398A1/en not_active Abandoned
- 2021-01-08 US US17/145,233 patent/US20210130399A1/en not_active Abandoned
- 2021-06-17 JP JP2021100792A patent/JP2021138769A/ja active Pending

Also Published As

Publication number	Publication date
IL262513B (en)	2022-09-01
IL257192B (en)	2021-02-28
HUE033623T2 (en)	2017-12-28
JP2021138769A (ja)	2021-09-16
EP3388452A3 (en)	2019-02-20
US10501491B2 (en)	2019-12-10
CY1119024T1 (el)	2018-01-10
IL167041A (en)	2015-05-31
ES2629602T3 (es)	2017-08-11
EP2332996A1 (en)	2011-06-15
CA2496060C (en)	2015-08-04
US20190352332A1 (en)	2019-11-21
EP1543038B1 (en)	2017-05-31
IL238540A0 (en)	2015-06-30
PT1543038T (pt)	2017-07-07
IL262513A (en)	2018-12-31
IL257192A (en)	2018-03-29
EP1543038A4 (en)	2008-01-23
US20120065381A1 (en)	2012-03-15
EP3388452A2 (en)	2018-10-17
AU2003265994A1 (en)	2004-04-30
CA2496060A1 (en)	2004-03-25
DK2332996T3 (da)	2014-12-15
US20210171571A1 (en)	2021-06-10
SI1543038T1 (sl)	2017-07-31
DK1543038T3 (da)	2017-07-10
US20190352331A1 (en)	2019-11-21
US20040082047A1 (en)	2004-04-29
WO2004024866A3 (en)	2004-10-14
JP2010053154A (ja)	2010-03-11
LT1543038T (lt)	2017-07-10
JP5303092B2 (ja)	2013-10-02
SI1543038T2 (sl)	2020-12-31
JP2019043953A (ja)	2019-03-22
JP2012214523A (ja)	2012-11-08
EP1543038A2 (en)	2005-06-22
EP1543038B2 (en)	2020-08-05
US20150072918A1 (en)	2015-03-12
US8044017B2 (en)	2011-10-25
ES2527616T3 (es)	2015-01-27
US20210130398A1 (en)	2021-05-06
AU2003265994B2 (en)	2010-04-01
JP2015131847A (ja)	2015-07-23
JP2005538176A (ja)	2005-12-15
WO2004024866A2 (en)	2004-03-25
US9868760B2 (en)	2018-01-16
AU2010202784A1 (en)	2010-07-22
JP2017095497A (ja)	2017-06-01
US20190352333A1 (en)	2019-11-21
US20210130399A1 (en)	2021-05-06
EP2332996B1 (en)	2014-10-15
US8710196B2 (en)	2014-04-29
IL238541A0 (en)	2015-06-30
ES2629602T5 (es)	2021-06-08
HK1158223A1 (en)	2012-07-13
US20180244715A1 (en)	2018-08-30

Publication	Publication Date	Title
DK1543038T4 (da)	2020-11-09	Proteinoprensning
ATE457980T1 (de)	2010-03-15	Aryloxime
ATE534648T1 (de)	2011-12-15	C-6-modifizierte indazolylpyrrolotriazine
EP1557594A4 (en)	2006-01-18	OIL RING
ATE427876T1 (de)	2009-04-15	Luftkissenboot
ATE318817T1 (de)	2006-03-15	Aza-arylpiperazine
DE50212360D1 (de)	2008-07-24	Anfahrhilfesteuerungsvorrichtung
DE50212349D1 (de)	2008-07-17	Hirurgie
ATE349458T1 (de)	2007-01-15	Etonogestrelester
ATA1572002A (de)	2003-06-15	Managementspleisskassette
DE60320941D1 (de)	2008-06-26	Amidoacetonitrilderivate
ATA4142004A (de)	2005-12-15	Trägerverbau
ATE469773T1 (de)	2010-06-15	Zugöse
ATA19152002A (de)	2004-11-15	Hubkupplung
DE50209283D1 (de)	2007-03-08	Tropfbewässerungsrohr
ATE396192T1 (de)	2008-06-15	N-sulfonylaminothiazole
DE10244834B8 (de)	2005-01-13	Suszeptometer
DE50300322D1 (de)	2005-03-31	Zylinderkopfdichtung
NO20053512D0 (no)	2005-07-18	IL-8-liknende proteiner
NO20052608D0 (no)	2005-05-31	Midkinlignende protein
NO20050436D0 (no)	2005-01-26	Beta-lagnedbrytende peptider
ATA16872002A (de)	2005-06-15	Zwischenstück
DE10211707A8 (de)	2005-05-04	Segmentstatormaschine
ATA522002A (de)	2003-07-15	Vmp-bindungsprotein
DE50207561D1 (de)	2006-08-31	Gurthöhenverstellteil